5-溴-6-硝基-1H-吲唑 | 71785-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 5-溴-6-硝基-1H-吲唑
• 中文别名: 5-溴-6-硝基吲唑
• 英文名称: 5-bromo-6-nitro-1H-indazole
• CAS: 71785-49-4
• 化学式: C₇H₄BrN₃O₂
• 分子量: 242.032
• InChiKey: ATTOIRAMFAFXNA-UHFFFAOYSA-N

物化性质

• 沸点：
  389.6±22.0 °C(Predicted)
• 密度：
  1.965±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  5-溴-3-氯-6-硝基-1氢-吲唑	5-bromo-3-chloro-6-nitro-1H-indazole	929617-32-3	C7H3BrClN3O2	276.477
  ——	tert-butyl 5-bromo-6-nitro-1H-indazole-1-carboxylate	929617-38-9	C12H12BrN3O4	342.149

反应信息

• 作为反应物：
  描述：

  5-溴-6-硝基-1H-吲唑 在 盐酸 、 platinum(IV) oxide 、 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 copper(l) iodide 、 四(三苯基膦)钯 、 水 、 氢气 、 碘 、 铜 、 sodium carbonate 、 potassium carbonate 、 对甲苯磺酸 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 二丁醚 、 水 、 二甲基亚砜 、 乙酸乙酯 、 甲苯 为溶剂， 反应 73.5h， 生成 9-chloro-3,6-dihydropyrazolo[3,4-c]carbazol-5-amine
  参考文献：
  名称：

  Identification of 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyrazolo[3,4-c]carbazoles as new Pim kinase inhibitors

  摘要：

  New 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyrazolo[3,4-c]carbazoles were prepared and evaluated for their Pim kinase inhibitory potencies as well as their antiproliferative activities toward two prostatic cancer cell lines. Pyrazolocarbazole 15a was found to be a potent Pim kinase modulator with inhibitory potency toward the three isoforms. Compound 6c strongly inhibited Pim-3 with weaker effect toward Pim-1 and Pim-2, and thus could be used as an interesting molecular tool to study Pim-3 biological functions. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.011
• 作为产物：
  描述：

  4-溴-2-甲基-5-硝基苯胺 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 72.0h， 以63%的产率得到5-溴-6-硝基-1H-吲唑
  参考文献：
  名称：

  Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt

  摘要：

  Thr-211 is one of three different amino acid residues in the kinase domain of protein kinase B/Akt as compared to protein kinase A (PKA), a closely related analog in the same AGC family. In an attempt to improve the potency and selectivity of our indazole-pyridine series of Akt inhibitors over PKA, efforts have focused on the incorporation of a chemical functionality to interact with the hydroxy group of Thr-211. Several substituents including an oxygen anion, amino, and nitro groups have been introduced at the C-6 position of the indazole scaffold, leading to a significant drop in Akt potency. Incorporation of a nitrogen atom into the phenyl ring at the same position (i.e., 9f) maintained the Akt activity and, in some cases, improved the selectivity over PKA. The structure-activity relationships of the new pyridine-pyrazolopyridine series of Akt inhibitors and their structural features when bound to PKA are also discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.010

文献信息

• [EN] INHIBITORS OF ERK AND METHODS OF USE<br/>[FR] INHIBITEURS D'ERK ET MÉTHODES D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2015051341A1

  公开（公告）日：2015-04-09

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.

  本发明提供了能够调节某些蛋白激酶（如ERK（MAPK））的化学实体或化合物以及其药物组合物。还提供了使用这些化合物或组合物的方法，以及使用这些组合物调节这些激酶中一个或多个的活性的方法，特别是用于治疗癌症等疾病的治疗应用。
• [EN] MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES UTILISÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011100401A1

  公开（公告）日：2011-08-18

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了以下式（I）的化合物：或其立体异构体、互变异构体或药用可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• 三并环类衍生物抑制剂、其制备方法和应用
  申请人：上海翰森生物医药科技有限公司

  公开号：CN109761986B

  公开（公告）日：2021-10-08

  本发明涉及三并环类衍生物抑制剂、其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为蛋白酶如ERK(MAPK)抑制剂在治疗癌症、骨病、炎性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸性疾病和心脏病的用途，其中通式(I)中的各取代基与说明书中的定义相同。
• Therapeutic substituted indazole derivatives
  申请人：Malmstrom Jonas

  公开号：US20050113370A1

  公开（公告）日：2005-05-26

  The invention provides a compound of Formula I Formula I wherein R 1 is aryl or heteroaryl each of which is optionally substituted with one or more of the following R 3 , —OR 3 , —OCOR 3 , —COOR 3 , —COR 3 , —CONR 3 R 4 , —NHCOR 3 , —NR 3 R 4 , —NHSO 2 R 3 , —S 2 R 3 , —SO 2 NR 3 R 4 , —SR 3 , CN, halogeno or NO 2 ; R 2 is NO 2 , NH 2 , —NR 5 R 6 or —NR 6 R 7 ; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  该发明提供了一种公式I的化合物，其中R1是芳基或杂环芳基，可选择地取代为以下一种或多种：R3，—OR3，—OCOR3，—COOR3，—COR3，—CONR3R4，—NHCOR3，—NR3R4，—NHSO2R3，—S2R3，—SO2NR3R4，—SR3，CN，卤素或NO2；R2是NO2，NH2，—NR5R6或—NR6R7；作为自由碱基或药学上可接受的盐、溶剂或其盐的溶剂，还提供了制备这些化合物的方法、含有该化合物的制药配方以及该化合物在治疗中的使用。
• MACROCYCLES AS FACTOR XIA INHIBITORS
  申请人：Corte James R.

  公开号：US20120041190A1

  公开（公告）日：2012-02-16

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如此定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆卡利肌酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。